• linkedin
  • Increase Font
  • Sharebar

    Kidney Ca: Cytoreductive nephrectomy appears to be protective


    An examination of metastasectomy trends in the National Cancer Database showed improved survival in patients undergoing metastasectomy and chemotherapy compared to chemotherapy alone. Despite this, rates of metastasectomy have been dropping in recent years, suggesting potential undertreatment in this population. In a parallel study looking at more than 13,000 metastatic kidney cancer patients, improved survival was seen following cytoreductive nephrectomy, with a difference of 16.8 months versus 8 months and a hazard ratio of 0.4. Even in the targeted therapy era, it appears that cytoreductive nephrectomy is protective.


    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available